Treatment of chronic rhinosinusitis with high-dose oral terbinafine: A double blind, placebo-controlled study

David W. Kennedy, F. A. Kuhn, D. L. Hamilos, Simion J Zinreich, D. Butler, G. Warsi, P. J. Poster, A. Tavakkol

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate antifungal terbinafine in patients with chronic rhinosinusitis. Study Design: Randomized, double-blind, placebo-controlled multicenter pilot study. Methods: Fifty-three adults with chronic rhinosinusitis received terbinafine 625 mg/ day (n = 25) or placebo (n = 28) once daily for 6 weeks. Sinus secretions were collected at screening for mycology. Computed tomography was graded for extent of opacification at baseline and at week 6 using a modification of the Lund-Mackay scoring system. Patients recorded rhinosinusitis symptoms on a visual analogue scale and completed the Rhinosinusitis Disability Index. Results: Positive fungal cultures were found in 41 of 53 patients (17 terbinafine, 24 placebo). (Two subjects from the Terbinafine group and one subject from the control group had no week 6 data). The mean opacification scores pre- and posttreatment for the entire study group improved from 24.2 to 22.5 in placebo (n = 26) and from 26.3 to 24.2 in terbinafine group (n = 23). The least squares means for percent change from baseline (SE) were -6.0 (8.7) for placebo compared with -7.2 (8.1) for terbinafine; 95% confidence interval for treatment difference (-18.9, 21.1); P = .91. Results were similar when only patients with positive fungal cultures were evaluated in the efficacy analysis. Investigator therapeutic evaluations and sinus symptom scores were not significantly different between the two groups at baseline or at treatment completion. Conclusion: Treatment with terbinafine failed to improve the symptoms or radiographic appearance of chronic rhinosinusitis even when nasal irrigation samples were positive for fungus on culture. One consideration is that the fungi isolated were not a major pathologic factor in this cohort. It is also possible that, even at high dose, terbinafine may not have maintained therapeutic levels in the nasal secretions.

Original languageEnglish (US)
Pages (from-to)1793-1799
Number of pages7
JournalLaryngoscope
Volume115
Issue number10 I
DOIs
StatePublished - Oct 2005

Fingerprint

terbinafine
Placebos
Therapeutics
Fungi
Nasal Lavage
Mycology
Symptom Assessment
Least-Squares Analysis
Visual Analog Scale
Nose

Keywords

  • Children
  • Chronic rhinosinusitis
  • Lacrimal
  • Oral terbinafine

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Treatment of chronic rhinosinusitis with high-dose oral terbinafine : A double blind, placebo-controlled study. / Kennedy, David W.; Kuhn, F. A.; Hamilos, D. L.; Zinreich, Simion J; Butler, D.; Warsi, G.; Poster, P. J.; Tavakkol, A.

In: Laryngoscope, Vol. 115, No. 10 I, 10.2005, p. 1793-1799.

Research output: Contribution to journalArticle

Kennedy, DW, Kuhn, FA, Hamilos, DL, Zinreich, SJ, Butler, D, Warsi, G, Poster, PJ & Tavakkol, A 2005, 'Treatment of chronic rhinosinusitis with high-dose oral terbinafine: A double blind, placebo-controlled study', Laryngoscope, vol. 115, no. 10 I, pp. 1793-1799. https://doi.org/10.1097/01.mlg.0000175683.81260.26
Kennedy, David W. ; Kuhn, F. A. ; Hamilos, D. L. ; Zinreich, Simion J ; Butler, D. ; Warsi, G. ; Poster, P. J. ; Tavakkol, A. / Treatment of chronic rhinosinusitis with high-dose oral terbinafine : A double blind, placebo-controlled study. In: Laryngoscope. 2005 ; Vol. 115, No. 10 I. pp. 1793-1799.
@article{02b2d60d850f4439a40fca4a65d79a89,
title = "Treatment of chronic rhinosinusitis with high-dose oral terbinafine: A double blind, placebo-controlled study",
abstract = "Objectives: To evaluate antifungal terbinafine in patients with chronic rhinosinusitis. Study Design: Randomized, double-blind, placebo-controlled multicenter pilot study. Methods: Fifty-three adults with chronic rhinosinusitis received terbinafine 625 mg/ day (n = 25) or placebo (n = 28) once daily for 6 weeks. Sinus secretions were collected at screening for mycology. Computed tomography was graded for extent of opacification at baseline and at week 6 using a modification of the Lund-Mackay scoring system. Patients recorded rhinosinusitis symptoms on a visual analogue scale and completed the Rhinosinusitis Disability Index. Results: Positive fungal cultures were found in 41 of 53 patients (17 terbinafine, 24 placebo). (Two subjects from the Terbinafine group and one subject from the control group had no week 6 data). The mean opacification scores pre- and posttreatment for the entire study group improved from 24.2 to 22.5 in placebo (n = 26) and from 26.3 to 24.2 in terbinafine group (n = 23). The least squares means for percent change from baseline (SE) were -6.0 (8.7) for placebo compared with -7.2 (8.1) for terbinafine; 95{\%} confidence interval for treatment difference (-18.9, 21.1); P = .91. Results were similar when only patients with positive fungal cultures were evaluated in the efficacy analysis. Investigator therapeutic evaluations and sinus symptom scores were not significantly different between the two groups at baseline or at treatment completion. Conclusion: Treatment with terbinafine failed to improve the symptoms or radiographic appearance of chronic rhinosinusitis even when nasal irrigation samples were positive for fungus on culture. One consideration is that the fungi isolated were not a major pathologic factor in this cohort. It is also possible that, even at high dose, terbinafine may not have maintained therapeutic levels in the nasal secretions.",
keywords = "Children, Chronic rhinosinusitis, Lacrimal, Oral terbinafine",
author = "Kennedy, {David W.} and Kuhn, {F. A.} and Hamilos, {D. L.} and Zinreich, {Simion J} and D. Butler and G. Warsi and Poster, {P. J.} and A. Tavakkol",
year = "2005",
month = "10",
doi = "10.1097/01.mlg.0000175683.81260.26",
language = "English (US)",
volume = "115",
pages = "1793--1799",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "10 I",

}

TY - JOUR

T1 - Treatment of chronic rhinosinusitis with high-dose oral terbinafine

T2 - A double blind, placebo-controlled study

AU - Kennedy, David W.

AU - Kuhn, F. A.

AU - Hamilos, D. L.

AU - Zinreich, Simion J

AU - Butler, D.

AU - Warsi, G.

AU - Poster, P. J.

AU - Tavakkol, A.

PY - 2005/10

Y1 - 2005/10

N2 - Objectives: To evaluate antifungal terbinafine in patients with chronic rhinosinusitis. Study Design: Randomized, double-blind, placebo-controlled multicenter pilot study. Methods: Fifty-three adults with chronic rhinosinusitis received terbinafine 625 mg/ day (n = 25) or placebo (n = 28) once daily for 6 weeks. Sinus secretions were collected at screening for mycology. Computed tomography was graded for extent of opacification at baseline and at week 6 using a modification of the Lund-Mackay scoring system. Patients recorded rhinosinusitis symptoms on a visual analogue scale and completed the Rhinosinusitis Disability Index. Results: Positive fungal cultures were found in 41 of 53 patients (17 terbinafine, 24 placebo). (Two subjects from the Terbinafine group and one subject from the control group had no week 6 data). The mean opacification scores pre- and posttreatment for the entire study group improved from 24.2 to 22.5 in placebo (n = 26) and from 26.3 to 24.2 in terbinafine group (n = 23). The least squares means for percent change from baseline (SE) were -6.0 (8.7) for placebo compared with -7.2 (8.1) for terbinafine; 95% confidence interval for treatment difference (-18.9, 21.1); P = .91. Results were similar when only patients with positive fungal cultures were evaluated in the efficacy analysis. Investigator therapeutic evaluations and sinus symptom scores were not significantly different between the two groups at baseline or at treatment completion. Conclusion: Treatment with terbinafine failed to improve the symptoms or radiographic appearance of chronic rhinosinusitis even when nasal irrigation samples were positive for fungus on culture. One consideration is that the fungi isolated were not a major pathologic factor in this cohort. It is also possible that, even at high dose, terbinafine may not have maintained therapeutic levels in the nasal secretions.

AB - Objectives: To evaluate antifungal terbinafine in patients with chronic rhinosinusitis. Study Design: Randomized, double-blind, placebo-controlled multicenter pilot study. Methods: Fifty-three adults with chronic rhinosinusitis received terbinafine 625 mg/ day (n = 25) or placebo (n = 28) once daily for 6 weeks. Sinus secretions were collected at screening for mycology. Computed tomography was graded for extent of opacification at baseline and at week 6 using a modification of the Lund-Mackay scoring system. Patients recorded rhinosinusitis symptoms on a visual analogue scale and completed the Rhinosinusitis Disability Index. Results: Positive fungal cultures were found in 41 of 53 patients (17 terbinafine, 24 placebo). (Two subjects from the Terbinafine group and one subject from the control group had no week 6 data). The mean opacification scores pre- and posttreatment for the entire study group improved from 24.2 to 22.5 in placebo (n = 26) and from 26.3 to 24.2 in terbinafine group (n = 23). The least squares means for percent change from baseline (SE) were -6.0 (8.7) for placebo compared with -7.2 (8.1) for terbinafine; 95% confidence interval for treatment difference (-18.9, 21.1); P = .91. Results were similar when only patients with positive fungal cultures were evaluated in the efficacy analysis. Investigator therapeutic evaluations and sinus symptom scores were not significantly different between the two groups at baseline or at treatment completion. Conclusion: Treatment with terbinafine failed to improve the symptoms or radiographic appearance of chronic rhinosinusitis even when nasal irrigation samples were positive for fungus on culture. One consideration is that the fungi isolated were not a major pathologic factor in this cohort. It is also possible that, even at high dose, terbinafine may not have maintained therapeutic levels in the nasal secretions.

KW - Children

KW - Chronic rhinosinusitis

KW - Lacrimal

KW - Oral terbinafine

UR - http://www.scopus.com/inward/record.url?scp=26944431555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944431555&partnerID=8YFLogxK

U2 - 10.1097/01.mlg.0000175683.81260.26

DO - 10.1097/01.mlg.0000175683.81260.26

M3 - Article

C2 - 16222197

AN - SCOPUS:26944431555

VL - 115

SP - 1793

EP - 1799

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 10 I

ER -